Published 5 days ago • loading... • Updated 5 days ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Innovent announced that seven products were included in the updated 2025 NRDL, effective January 1, 2026, with the update announced in SAN FRANCISCO and SUZHOU, China.
Guided by its patient-centered mission, Innovent said the NRDL inclusions aim to broaden patient access and enhance affordability, benefiting patients in China through partnerships with over 30 global healthcare companies.
Limertinib's chemistry includes a naphthylamine group that increases lipophilicity and enhances blood-brain barrier penetration, Innovent said, with exclusive rights in Mainland China.
SYCUME's NRDL listing targets moderate-to-severe thyroid eye disease by blocking IGF-1R, while TYVYT with fruquintinib and Jaypirca expand options for heavily-treated cancer patients.
By holding exclusive Mainland China rights, Innovent strengthens its position with Retsevmo, the first RET inhibitor approved globally for NSCLC and thyroid cancer with RET alteration.

Insights by Ground AI

48 Articles

The Billings Gazette

+47 Reposted by 47 other sources

Center

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…

5 days ago·Billings, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year